

Special Issue

Herpes Simplex Virus Infection, Immunity, and Vaccine Development

Message from the Guest Editors

Herpes Simplex Virus (HSV) infections affect people around the world, with HSV-1 and HSV-2 causing significant morbidity through recurrent oral-facial, ocular, and genital lesions. Despite decades of pre-clinical and clinical research, no licensed HSV vaccines or immunotherapeutic agents are currently available. We encourage submissions on the following topics:

- Herpes simplex infection and immunity in animal models and humans
- Multi-omics data to better phenotype, differentiate, and classify immune responses
- Immunological and virological factors contributing protection or exacerbating recurrent herpes infection and disease
- Immune regulation, immune evasion, immune checkpoints, and immuno-regulatory pathways
- Pre-clinical and clinical evaluation of HSV vaccine and immunotherapeutic candidates
- Innovative vaccine and immunotherapeutic platforms, adjuvants, and delivery systems
- Identification of protective B- and T-cell antigens/epitopes
- Innate and adaptive immunological correlates of protection
- Therapeutic vaccination strategies for individuals with established HSV
- Mucosal immunity considerations in HSV vaccine design
- Regulatory challenges for HSV vaccines

Guest Editors

Prof. Dr. Lbachir BenMohamed

Institute for Immunology, School of Medicine, University of California Irvine, Irvine, CA 92697, USA

Dr. Swayam Prakash

Institute for Immunology, School of Medicine, University of California Irvine, Irvine, CA 92697, USA

Deadline for manuscript submissions

31 December 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/236937

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).